# Validation of a Predictive Model of Response to Romiplostim in Patients With IPSS Low or Intermediate-1 Risk MDS and Thrombocytopenia

> **NCT02335268** · PHASE2 · COMPLETED · sponsor: **Gesellschaft fur Medizinische Innovation - Hamatologie und Onkologie mbH** · enrollment: 77 (actual)

## Conditions studied

- Myelodysplastic Syndromes

## Interventions

- **DRUG:** N-Plate / romiplostim

## Key facts

- **NCT ID:** NCT02335268
- **Lead sponsor:** Gesellschaft fur Medizinische Innovation - Hamatologie und Onkologie mbH
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-05-21
- **Primary completion:** 2021-07-01
- **Final completion:** 2021-07-01
- **Target enrollment:** 77 (ACTUAL)
- **Last updated:** 2023-08-16

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02335268

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02335268, "Validation of a Predictive Model of Response to Romiplostim in Patients With IPSS Low or Intermediate-1 Risk MDS and Thrombocytopenia". Retrieved via AI Analytics 2026-07-13 from https://api.ai-analytics.org/clinical/NCT02335268. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*